Silke Meier's research while affiliated with Goethe-Universität Frankfurt am Main and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (3)
The validation of a LC/MS/MS method for the determination of 8-methoxypsoralen (8-MOP) in human plasma and microdialysates after topical application is described. Plasma samples were extracted by liquid-liquid extraction with diisopropylether using 4,5',8-trimethylpsoralen (TMP) as internal standard. Chromatographic separation of plasma sample extr...
This placebo-controlled, double-blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short-term (2 h) low dose infusion of morphine-6-beta-glucuronide (M6G) because M6G does not pass the blood-brain barrier...
The combination of 8-methoxypsoralen with ultraviolet A exposure (PUVA therapy) is a standard treatment for a variety of dermatoses. The following three variants have been described: oral, bath, or cream PUVA. To achieve optimal therapeutic effects, ultraviolet A irradiation should be performed at the time of maximum photosensitivity, that is, at t...
Citations
... Appropriate amount of umbelliferone, nodakenin, psoralen, xanthotoxin and bergapten was weighted precisely and dissolved with methanol to obtain stock standard solution with the concentration of 42.0000, 41.0000, 41.0000, 86.0000 and 56.0000 μg·mL −1 , respectively. The standard solution above was stored at 4 • C. Standard solution was precisely absorbed and dissolved with methanol (finally adjusted volume 5 mL) to obtain the mixed standard solution with concentration of umbelliferone (0.0672, 1.3440, 6.7200, 16.8000 and 42.000 μg·mL −1 ), nodakenin (0.0656, 1.3120, 6.5600, 16.4000 and 41.0000 μg·mL −1 ), psoralen (0.0656, 1.3120, 6.5600, 16.4000 and 41.0000 μg·mL −1 ), xanthotoxin (0.1376, 2.7520, 13.7600, 34.4000 and 86.0000 μg·mL −1 ), bergapten (0.0896, 1.7920, 8.9600, 22.4000 and 56.0000 μg·mL −1 ). The solution was shaken well and filtered through a 0.45 μm membrane filter before UPLC analysis. ...
... Opioid agonists exert their antinociceptive actions through the activation of opioid receptors, particularly µ-opioid receptors (MORs), both peripherally and centrally (spinal and supraspinal MOR activation) [2]. Although the site of action of clinically available analgesics is considered to be central, MOR-mediated peripheral analgesia has also been identified in human and experimental pain models [3][4][5][6][7][8][9][10]. The current consensus is that opioid agonists are the most effective analgesics for treating mild to severe acute and chronic pain types, yet in the case of neuropathic pain, their effect is up for debate [11][12][13]. ...
... Under our experimental conditions, however, the expression of CYP1A1 and CYP1A2 mRNAs and CYP1A2 protein was significantly increased at 5 μM xanthotoxin (Fig. 2), albeit CYP1A1 protein expression was elevated only at 10 μM of xanthotoxin after 72 h treatment. On the other hand, when this compound was orally administered in human (1 mg/kg body weight), the plasma concentration of xanthotoxin was shown to be the highest after 2 h while the concentration was approximately 1.6 ng/mL (Brautigam et al. 2003). Although it is difficult to extrapolate such effects to metabolic outcomes because of the inherent limitations of in vitro experiments, it is important to note that dietary exposure to O. javanica may modulate phase I enzymes and thereby affect various xenobiotic metabolism. ...